Uveitis Treatment Trials—A Cross-study Perspective

Click to increase image sizeClick to decrease image size

ACKNOWLEDGEMENT

Supported in part by The Pacific Vision Foundation (ETC), The San Francisco Retina Foundation (ETC), and an unrestricted grant from Research to Prevent Blindness, New York, NY, USA (DAG). We thank Nisha R. Acharya, John H. Kempen, and James T. Rosenbaum for thoughtfully reading and commenting on an early version of this editorial. Three and six month response rates and three, six, nine, and twelve month confidence intervals for the MUST Trial arms provided by Elizabeth Sugar, PhD on behalf of the Must Trial Research Group.

Declaration of interest: DAG: Advisory board, research support, honoraria: Abbott, Allergan, Bausch & Lomb, GSK, Lux biosciences, Santen. MZ: Advisory board: Allergan, Bausch & Lomb, GSK, Lux Biosciences. ETC has no financial interests.